Is OPCH a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Option Care Health (OPCH) rests on The pending CD&R and McKesson take-private: The dominant factor for OPCH now is the $32.05-per-share cash offer. The bear case rests on the central risk is deal risk. Analysts covering it publish targets from $23.00 to $33.00 against a $31.20 price, so even the professionals disagree by 33% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share. The picture changed in early October 2026. Private-equity firm Clayton, Dubilier & Rice and drug distributor McKesson agreed to acquire Option Care for $32.05 per share in cash, valuing the company at about $5.8 billion including debt and representing a premium of roughly 37% over the October 5 close. CD&R is expected to own about 51% and McKesson about 49% at closing, with McKesson investing about $1.4 billion and gaining a framework to potentially buy CD&R's interest later. The deal needs Option Care shareholder approval and regulatory clearances, and it is expected to close in the first half of 2027, after which the shares would stop trading on Nasdaq. Option Care withdrew its 2026 guidance and said it will remain a separate company led by its existing management. Before the offer, the business was a defensive, cash-generative operator working through a soft patch. Trailing revenue is about $5.69 billion, growing only about 2% in the latest quarter as chronic-inflammatory-drug (CID) portfolio headwinds, including Stelara and biosimilar census resets, dragged on the top line. Trailing net income is about $210 million on a thin 3.7% profit margin, because much of the revenue is drug pass-through cost. The shares jumped on the announcement: they were up about 44% over three months as of October 16, 2026, roughly flat for the year (down about 3% year to date), and several brokers, including Jefferies, UBS, Barrington and Morgan Stanley, downgraded the stock to neutral-style ratings since the remaining upside is limited to the deal price.
The bull case: what would have to be true for $33.00
The most optimistic published target on OPCH is $33.00, +5.8% from the $31.20 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The pending CD&R and McKesson take-private
The dominant factor for OPCH now is the $32.05-per-share cash offer. With the stock near $31.27 on October 16, 2026, the gap to the offer price is roughly 2.5%, which is the market's pay for waiting until an expected first-half 2027 close and for bearing the risk that shareholder or regulatory approval falls through. Holders who stay through closing would receive cash and no ongoing stake in the business.
2. Acute infusion demand and hospital partnerships
Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. As health systems push to move care out of expensive hospital settings, Option Care's national footprint positions it to capture referral volume and consolidate patients, including some exiting CVS Coram's acute business. McKesson's CEO framed the deal around expanding access to complex therapies in lower-cost community settings.
3. Cash generation and operating results through closing
The company converts earnings into meaningful free cash flow, about $256 million on a trailing basis against roughly $347 million of operating cash flow. Quarterly results have kept edging past estimates: second-quarter 2026 EPS of about $0.45 beat the roughly $0.43 consensus on revenue of about $1.44 billion. Option Care will report third-quarter results on November 4, 2026 without a live earnings call, and those numbers matter mainly as a check that nothing in the business threatens the deal.
4. Structural tailwind from site-of-care migration
The broader home-infusion market is estimated to grow at a mid-single-digit to low-double-digit rate as payers and patients favor lower-cost home settings over hospitals and clinics. That tailwind is a large part of why a distributor like McKesson wanted a stake, but after closing public shareholders would no longer participate in it.
The bear case: what would have to be true for $23.00
The most pessimistic published target is $23.00, -26.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Option Care Health is worth if the risks below bite instead of the drivers above.
The central risk is deal risk. The take-private requires Option Care shareholder approval and regulatory approvals, and a combination involving a major drug distributor could draw antitrust scrutiny; a legal review of the proposed takeover has also been reported. If the deal broke, the shares could fall back toward pre-announcement levels, since the 37% premium is what lifted them. The upside is effectively capped near $32.05 while the deal is pending, and the time to an expected first-half 2027 close ties up capital. The underlying business risks still matter if the deal fails: the CID drug-portfolio headwind tied to Stelara and biosimilar transitions, thin gross margins (about 19%) on high drug pass-through revenue, sensitivity to reimbursement and payer contract terms, competition from CVS Coram and Optum-affiliated Naven Health, and about $1.27 billion of debt against roughly $197 million of cash.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding OPCH already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on OPCH
8 analysts cover OPCH, with an average target of $30.03 (-3.7% against $31.20) and a split of 0 buy, 11 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the OPCH forecast and price target page.
How is OPCH valued? (as of October 2026)
Snapshot for OPCH as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Deal price: $32.05 per share in cash (CD&R and McKesson)
- Deal value: ~$5.8B including debt
- Expected close: First half of 2027
- Revenue (TTM): ~$5.69B (~+2% YoY in Q2 2026)
- Net income (TTM): ~$210M (~3.7% margin)
- Market cap: ~$4.7B
- P/E (trailing / forward): ~24x / ~15x
OPCH's valuation is now set by the $32.05 cash offer rather than by earnings multiples. At a close near $31.27 on October 16, 2026, the stock trades about 2.5% below the deal price, a spread that reflects time to closing and the risk the transaction is blocked or voted down. Option Care withdrew its 2026 guidance on announcing the deal, so the earlier profit targets no longer apply.
How do you decide if OPCH is a buy?
Rather than asking whether OPCH is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold OPCH indirectly through an index or sector ETF before adding more.
What would change your mind on OPCH
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The pending CD&R and McKesson take-private stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the central risk is deal risk fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the OPCH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OPCH against your real portfolio and see your actual exposure before deciding.
Investing in Option Care Health with AI
Connect the broker you already use and ask Walnut's AI how OPCH fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is OPCH a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The pending CD&R and McKesson take-private, with revenue (ttm) at ~$5.69B (~+2% YoY in Q2 2026). The bear case rests on the central risk is deal risk. Analysts covering it are spread from $23.00 to $33.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell OPCH?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is deal risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $23.00, -26.3% from the $31.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for OPCH?
+
The pending CD&R and McKesson take-private. The dominant factor for OPCH now is the $32.05-per-share cash offer. The most optimistic analyst target on OPCH is $33.00, +5.8% from the $31.20 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for OPCH?
+
The central risk is deal risk. The take-private requires Option Care shareholder approval and regulatory approvals, and a combination involving a major drug distributor could draw antitrust scrutiny; a legal review of the proposed takeover has also been reported. If the deal broke, the shares could fall back toward pre-announcement levels, since the 37% premium is what lifted them. The upside is effectively capped near $32.05 while the deal is pending, and the time to an expected first-half 2027 close ties up capital. The underlying business risks still matter if the deal fails: the CID drug-portfolio headwind tied to Stelara and biosimilar transitions, thin gross margins (about 19%) on high drug pass-through revenue, sensitivity to reimbursement and payer contract terms, competition from CVS Coram and Optum-affiliated Naven Health, and about $1.27 billion of debt against roughly $197 million of cash. The most pessimistic published target is $23.00, -26.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Option Care Health do?
+
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (
What would have to change for OPCH to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The pending CD&R and McKesson take-private) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is deal risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Option Care Health do?
+
It provides infusion therapy, delivering medications intravenously or by other infusion routes in patients' homes and at alternate-site suites. Its therapies span acute needs like post-hospital antibiotics and nutrition and chronic conditions such as immune, neurologic, and inflammatory diseases.
Is Option Care Health being acquired?
+
Yes. In October 2026 Option Care agreed to be taken private by Clayton, Dubilier & Rice and McKesson for $32.05 per share in cash, about $5.8 billion including debt. CD&R would own about 51% and McKesson about 49%. The deal needs shareholder and regulatory approval and is expected to close in the first half of 2027, after which OPCH shares would stop trading.
Walnut is informational, not investment advice, and gives no verdict on OPCH. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.